NASDAQ · TRVI
Healthcare · Biotechnology
$13.86
Up+$0.13 (+0.90%)
Updated Nov 4, 2026, 11:02 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TRVI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
TRVI closed at $13.86 after 21 trading sessions, up 5.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $13.81 | $14.23 | $13.74 | $13.86 | 1.19M |
| Nov 2, 2026 | $13.70 | $13.805 | $13.21 | $13.63 | 1.47M |
| Oct 30, 2026 | $13.515 | $13.91 | $13.44 | $13.56 | 1.73M |
| Oct 29, 2026 | $13.65 | $14.06 | $13.465 | $13.81 | 1.35M |
| Oct 28, 2026 | $13.26 | $13.54 | $13.21 | $13.52 | 1.07M |
| Oct 27, 2026 | $12.63 | $13.445 | $12.50 | $13.35 | 2.1M |
| Oct 26, 2026 | $12.65 | $12.93 | $12.34 | $12.51 | 979.1K |
| Oct 23, 2026 | $12.74 | $12.74 | $12.39 | $12.61 | 1.38M |
| Oct 22, 2026 | $12.77 | $13.22 | $12.53 | $12.94 | 1.18M |
| Oct 21, 2026 | $12.77 | $13.30 | $12.72 | $12.77 | 2.65M |
| Oct 20, 2026 | $12.11 | $13.11 | $11.93 | $12.83 | 1.83M |
| Oct 19, 2026 | $12.00 | $12.22 | $11.745 | $11.90 | 1.6M |
| Oct 16, 2026 | $12.08 | $12.08 | $11.70 | $11.88 | 2.72M |
| Oct 15, 2026 | $12.06 | $12.385 | $11.985 | $12.11 | 1.71M |
| Oct 14, 2026 | $12.03 | $12.55 | $12.002 | $12.06 | 3.04M |
| Oct 13, 2026 | $12.86 | $13.19 | $12.29 | $12.29 | 1.58M |
| Oct 12, 2026 | $13.14 | $13.46 | $12.81 | $12.93 | 4.77M |
| Oct 9, 2026 | $13.09 | $13.30 | $12.5157 | $13.19 | 5.03M |
| Oct 8, 2026 | $12.96 | $13.28 | $12.325 | $12.825 | 6.35M |
| Oct 7, 2026 | $12.94 | $13.53 | $12.8407 | $13.14 | 5.37M |
| Oct 6, 2026 | $13.83 | $13.97 | $12.995 | $13.18 | 5M |
The latest Smart Investors Daily articles mentioning TRVI.
Company
Market Activity
Research & News
TRVI research
Company profile and research snapshot.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Jones Trading | Buy | — |
| Aug 7, 2026 | Oppenheimer | Outperform | — |
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 21, 2026 | BMO Capital | Outperform | — |
| Jul 20, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 13, 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary
Benzinga · Oct 12, 2026
Trevi Therapeutics (NASDAQ:TRVI) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Yahoo · Feb 17, 2026
Fireside chat with management on February 25, 2026, at 9:20 a.m. ETNEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chie
Yahoo · Jan 14, 2026
NEW HAVEN, Conn., January 14, 2026--BioCT, Connecticut’s life sciences trade organization, is pleased to announce the appointment of four distinguished executives to its Board of Directors. The organization has elected Ranjit Bindra, MD, PhD, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology at Yale School of Medicine and serial bioscience entrepreneur; Angela Cacace, PhD, Chief Scientific Officer, Arvinas; Jennifer Good, Co-Founder, President, and Chief Execu
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TRVI.
